Last updated: March 1, 2026
What Is NDC 70677-1291?
NDC 70677-1291 corresponds to Ruxolitinib tablets, marketed under the trade name Jakafi by Incyte Corporation. Approved by the FDA for myelofibrosis and polycythemia vera treatment, it is a JAK1/JAK2 inhibitor.
Market Size and Demand Drivers
Ruxolitinib primarily addresses rare blood disorders with limited competition, leading to a steady demand. The key indications include:
- Myelofibrosis
- Polycythemia vera (approved in 2019)
- Graft-versus-host disease (GvHD) (off-label, ongoing trials)
Estimates from IQVIA show U.S. sales of Jakafi reached $1.3 billion in 2022, with annual growth about 4-5% driven by expanding indications and increased penetration among eligible patients.
Competitive Landscape
Major competitors include Fedratinib (Inrebic), Pacritinib, and emerging pipeline agents. Competition remains limited due to the specialized nature of indications.
| Product |
Dosage/Indication |
2022 U.S. Sales |
Market Share |
| Jakafi |
Myelofibrosis, Polycythemia vera |
$1.3B |
80% |
| Inrebic |
Myelofibrosis |
~$100M |
8% |
| Pacritinib |
Myelofibrosis (investigational) |
N/A |
2% |
Price Analysis
The average wholesale price (AWP) for Jakafi has been stable over recent years, around $600 per tablet (30 mg dose), reflecting the following factors:
- Pricing Trends: Slight increase (~2%) annually, aligned with inflation adjustments.
- Reimbursement: Managed through Medicare, Medicaid, and private insurers, with copay assistance programs lowering patient out-of-pocket costs.
| Key Price Metrics |
2021 |
2022 |
2023 (Projected) |
| AWP per 30mg tablet |
$580 |
$595 |
$610 |
| Monthly treatment cost (assuming 90mg/day) |
~$1,710 |
~$1,755 |
~$1,800 |
| Annual per-patient costs |
~$20,500 |
~$21,060 |
~$21,600 |
Price Projections for 2024-2028
Considering current pricing trajectories, patent protections, and market dynamics, the following projections are established:
- 2024: A 1.5-2% increase in AWP, leading to approximately $620 per 30mg tablet. Annual per-patient costs would rise to about $21,800.
- 2025-2028: Compound annual growth rate (CAGR) around 2%; prices may reach $650-$700 per tablet by 2028, factoring in inflation, production costs, and market competition.
Market Trends and Risks
- Patent Expiry: Jakafi's basic patent expires in 2027; biosimilars and generic formulations could enter the market thereafter, exerting downward pressure on prices.
- Regulatory Developments: New indications or label expansions could increase demand, supporting stable pricing.
- Manufacturing and Supply: Supply chain disruptions or changes in pricing policies could alter cost structures.
Key Takeaways
- Steady demand for NDC 70677-1291 driven by its niche indications and limited competition.
- Pricing remains stable with slight annual increases, aligning with inflation.
- Market entry of biosimilars anticipated post-2027 could reduce prices significantly.
- Projected prices for 2024-2028 suggest minimal increases, with potential downward pressure from biosimilar competition after patent expiry.
- Total revenue estimate for 2023 remains around $1.3 billion, with gradual growth depending on indication expansion and market penetration.
FAQs
Q1: When does Jakafi's patent expire?
A1: Patents are expected to expire in 2027, with some formulation and method patents possibly extending protection.
Q2: How might biosimilars impact the price of NDC 70677-1291?
A2: Biosimilar entry could lower prices by 30-50%, depending on market acceptance and regulatory incentives.
Q3: Are there any upcoming approvals for additional indications?
A3: The label expansion for myelofibrosis and polycythemia vera continues, but no new FDA approvals are imminent as of 2023.
Q4: What are the key factors influencing future pricing?
A4: Patent expiration, competition, manufacturing costs, and regulatory changes.
Q5: How does Jakafi compare internationally?
A5: Pricing varies significantly by country; U.S. prices are among the highest globally, reflecting market exclusivity.
Citations
[1] IQVIA. (2023). Pharmaceutical Market Data.
[2] U.S. Food and Drug Administration. (2019). FDA approval of Jakafi for polycythemia vera.
[3] Incyte Corporation. (2023). Annual Report.
[4] CMS. (2023). Medicare Part B Pricing Data.
